Cipla (NSE:CIPLA) Other Current Payables: ₹7,341 Mil (As of Mar. 2026)


NSE:CIPLA Cipla Ltd NSE:CIPLA
94 GF Score
Price ₹1,439.40
GF Value ₹1,574.64
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Cipla Other Current Payables?

Cipla NSE:CIPLA -0.13% 94 Other Current Payables is ₹7,341 Mil as of Mar. 2026. GuruFocus rates NSE:CIPLA with a GF Score™ of 94/100 and a GF Value™ of ₹1,574.64 (Fairly Valued). The stock has 5 warning signs investors should review.

Cipla's Other Current Payables for the quarter that ended in Mar. 2026 was ₹7,341 Mil.

Cipla's quarterly Other Current Payables stayed the same from Sep. 2025 (₹0 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹7,341 Mil).

Cipla's annual Other Current Payables declined from Mar. 2024 (₹5,904 Mil) to Mar. 2025 (₹5,473 Mil) but then increased from Mar. 2025 (₹5,473 Mil) to Mar. 2026 (₹7,341 Mil).

Cipla Other Current Payables Related Terms

Cipla Other Current Payables Historical Data

* Premium members only.

The historical data trend for Cipla's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipla Other Current Payables Chart

Cipla Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,425.80 4,932.80 5,903.50 5,473.40 7,341.00

Cipla Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,473.40 0.00 0.00 0.00 7,341.00
NSE:CIPLA
94GF Score
Cipla Ltd NSE:CIPLA
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cipla Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ₹7,341 Mil mean?
Cipla (NSE:CIPLA) has a Other Current Payables of ₹7,341 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Cipla and its competitors.
Is Cipla's Other Current Payables too high?
Cipla's current Other Current Payables is ₹7,341 Mil. Overall, Cipla has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cipla's Other Current Payables compare to ZTS and UTHR?
Cipla's Other Current Payables of ₹7,341 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Cipla and its competitors. Cipla's current Other Current Payables is ₹7,341 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Based on GuruFocus' analysis, Cipla (NSE:CIPLA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,574.64, compared to a current price of ₹1,439.40 — trading 8.6% below its estimated fair value. The current Other Current Payables is ₹7,341 Mil. Cipla's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Cipla (NSE:CIPLA), the current Other Current Payables is ₹7,341 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipla (NSE:CIPLA) Overvalued in 2026?

Based on GuruFocus' analysis, Cipla stock appears to be undervalued. The current stock price of ₹1,439.40 is trading 8.6% below its estimated GF Value™ of ₹1,574.64. GuruFocus considers Cipla to be Fairly Valued.

Key valuation signals for NSE:CIPLA:

  • Other Current Payables: ₹7,341 Mil
  • GF Value™: ₹1,574.64 vs. price of ₹1,439.40 (8.6% below fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the NSE:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cipla Business Description

Other Exchanges 500087:India
Address Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
94GF Score

Get the complete analysis for NSE:CIPLA

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,439.40
Price
₹1,574.64
GF Value